Urothelial Cancer Of Renal Pelvis clinical trials

Explore recruiting urothelial cancer of renal pelvis clinical trials.

Recruiting urothelial cancer of renal pelvis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Urothelial Cancer Of Renal Pelvis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Spain, Italy, France, Germany, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Protocol Title: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

Hungary, Poland, Romania, Spain, Bulgaria, Latvia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low-Grade Upper Tract Urothelial Cancer

Germany, Austria, Spain, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

Italy, France, Sweden, Belgium, Greece, Ireland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

ADP-A2M4CD8 in advanced cancers

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Urothelial Cancer Of Renal Pelvis trials by city

Urothelial Cancer Of Renal Pelvis in Toronto Urothelial Cancer Of Renal Pelvis in Vancouver Urothelial Cancer Of Renal Pelvis in Montreal Urothelial Cancer Of Renal Pelvis in Calgary Urothelial Cancer Of Renal Pelvis in Edmonton Urothelial Cancer Of Renal Pelvis in Ottawa Urothelial Cancer Of Renal Pelvis in Winnipeg Urothelial Cancer Of Renal Pelvis in Quebec City Urothelial Cancer Of Renal Pelvis in Hamilton Urothelial Cancer Of Renal Pelvis in Kitchener Urothelial Cancer Of Renal Pelvis in London Urothelial Cancer Of Renal Pelvis in Halifax Urothelial Cancer Of Renal Pelvis in New York Urothelial Cancer Of Renal Pelvis in Los Angeles Urothelial Cancer Of Renal Pelvis in Chicago Urothelial Cancer Of Renal Pelvis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease